Werkgroep Cardiologische centra Nederland English

LATITUDE - deel A (Afgerond)

A Phase III outcomes trial that will compare the effects of losmapimod 7.5 mg twice daily (BID) for 12 weeks versus placebo when added to standard of care on the incidence of MACE in subjects with ACS (NSTEMI and STEMI).
Middel
losmapimod
Populatie
ASCVD
Fase
III
Jaar aanvang
2013
Meer informatie
ClinicalTrials.gov

Studiedirecteur

dr. A. Mosterd (Cardioloog)
Amersfoort, Meander Medisch Centrum